Patents by Inventor Juergen Soutschek

Juergen Soutschek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNAI MODULATION OF SCAP AND THERAPEUTIC USES THEREOF
    Publication number: 20160068840
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
    Type: Application
    Filed: July 8, 2015
    Publication date: March 10, 2016
    Inventors: Juergen SOUTSCHEK, Pamela TAN, Jay D. HORTON, Michael S. BROWN, Joseph L. GOLDSTEIN, Young-Ah MOON
  • RNAi modulation of ApoB and uses thereof
    Patent number: 9187747
    Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: November 17, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
  • RNAi modulation of SCAP and therapeutic uses thereof
    Patent number: 9102940
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: August 11, 2015
    Assignees: Alnylam Pharmaceuticals, Inc., Board of Regents, The University of Texas System
    Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
  • RNAi Modulation Of ApoB And Uses Thereof
    Publication number: 20140045922
    Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
    Type: Application
    Filed: October 21, 2013
    Publication date: February 13, 2014
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
  • RNAi modulation of APOB and uses thereof
    Patent number: 8592571
    Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: November 26, 2013
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
  • RNAi modulation of SCAP and therapeutic uses thereof
    Patent number: 8383805
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: February 26, 2013
    Assignees: Alnylam Pharmaceuticals, Inc., Board of Regents, The University of Texas System
    Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
  • RNAi Modulation of APOB and Uses Thereof
    Publication number: 20120252872
    Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
    Type: Application
    Filed: April 19, 2012
    Publication date: October 4, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
  • RNAi modulation of APOB and uses thereof
    Patent number: 8188061
    Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: May 29, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
  • RNAI MODULATION OF SCAP AND THERAPEUTIC USES THEREOF
    Publication number: 20110184047
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
    Type: Application
    Filed: April 5, 2011
    Publication date: July 28, 2011
    Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
  • RNAi modulation of SCAP and therapeutic uses thereof
    Patent number: 7919613
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: April 5, 2011
    Assignees: Alnylam Pharmaceuticals, Inc., Board of Regents, the Unversity of Texas System
    Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
  • RNAi Modulation of the RHO-A Gene and Uses Thereof
    Publication number: 20110071209
    Abstract: The invention relates to compositions and methods for modulating the expression of the RhoA gene, and more particularly to the downregulation of RhoA by chemically modified oligonucleotides.
    Type: Application
    Filed: July 30, 2010
    Publication date: March 24, 2011
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Juergen Soutschek, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • RNAi Modulation of APOB and Uses Thereof
    Publication number: 20100216866
    Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
    Type: Application
    Filed: March 19, 2010
    Publication date: August 26, 2010
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
  • iRNA agents targeted to the Rho-A gene
    Patent number: 7772200
    Abstract: The invention relates to compositions and methods for modulating the expression of the RhoA gene, and more particularly to the downregulation of RhoA by chemically modified oligonucleotides.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: August 10, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Juergen Soutschek, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • RNAI MODULATION OF SCAP AND THERAPEUTIC USES THEREOF
    Publication number: 20100184829
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
    Type: Application
    Filed: March 29, 2010
    Publication date: July 22, 2010
    Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
  • RNAi modulation of SCAP and therapeutics uses thereof
    Patent number: 7737266
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: June 15, 2010
    Assignees: Board of Regents, The University of Texas System, Alnylam Pharmaceuticals, Inc.
    Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
  • RNAi modulation of ApoB and uses thereof
    Patent number: 7723317
    Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: May 25, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
  • RNAi Modulation Of ApoB And Uses Thereof
    Publication number: 20090312397
    Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
    Type: Application
    Filed: March 9, 2009
    Publication date: December 17, 2009
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
  • RNAi modulation of ApoB and uses thereof
    Patent number: 7528118
    Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
    Type: Grant
    Filed: September 26, 2005
    Date of Patent: May 5, 2009
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
  • RNAI MODULATION OF SCAP AND THERAPEUTIC USES THEREOF
    Publication number: 20090093426
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
    Type: Application
    Filed: September 18, 2007
    Publication date: April 9, 2009
    Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
  • RNAi modulation of the Rho-A gene and uses thereof
    Publication number: 20070042984
    Abstract: The invention relates to compositions and methods for modulating the expression of the RhoA gene, and more particularly to the downregulation of RhoA by chemically modified oligonucleotides.
    Type: Application
    Filed: July 21, 2006
    Publication date: February 22, 2007
    Inventors: Juergen Soutschek, Pamela Tan, Anke Geick